Презентация по теме "Борьба с туберкулезом"
Данный инструмент должен использоваться для документирования клинического ведения пациентов, облегчения процесса обучения персонала на рабочем месте и обсужден...ия дальнейшего улучшения качества повседневной клинической практики.
more
презентация: Лечить пациента, а не болезнь: ориентированный на человека подход 7й симпозиум по вопросам лечения туберкулеза,
En este manual se presenta un método estandarizado para realizar, desde los centros de salud, encuestas transversales que permitan calcular los costos directos e indirectos que afectan a los pacientes con tuberculosis y a sus hogares, a partir de la experiencia acumulada con un instrumento diseñad...o previamente y un protocolo piloto probado por la OMS. El manual está dirigido especialmente a los programas nacionales de tuberculosis y a las entidades que colaboran en la planificación, ejecución, evaluación e Investigación operativa de los programas de tuberculosis.
more
“It has never been more urgent for us to come together to end HIV and tuberculosis. We achieve the most when we work together, using all of our strengths, harnessing all of our collective potential to end HIV and tuberculosis for a healthier world as part of the Sustainable Development Goals.” ...Michel Sisibé, Executive Director of UNAIDS
more
Презентация по оптимизация противотуберкулезной службы в Кыргызстане
Презентация на тему значимости скрининга больных с лекарственно-устойчивым туберкулезом на гепатит С. Как лучше всего лечить этих пациентов от гепатита С.
Regional snapshot: Eastern Europe and Central Asia
December 2018
https://data.unicef.org/wp-content/uploads/2018/11/EECA-regional-snapshot-2018.pdf
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med...icines for all patients with MDR-TB.
more
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
Stop TB`s GDF provides a wide range of diagnostic equipment and laboratory supplies in its Diagnostics Catalog
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis... of 50 studies involving 12,000 patients from 25 countries, published yesterday in The Lancet, found that bedaquiline, linezolid, levofloxacin, and moxifloxacin were associated with greater treatment success and reduced mortality compared with the previously recommended first-line treatments, while clofazimine and carbapenem antibiotics were associated with significantly improved treatment outcomes (but not reduced mortality)
more
In 2016 CRS leveraged the robust infrastructure of its large, multi-sectoral orphans and vulnerable children (OVC) program in Nigeria by expanding the program's core mandate to include community childhood TB casefinding, with a focus on highly vulnerable children and their caregivers
Healthy me, healthy us: a guide for community members about good health and staying healthy with chronic illness
La stratégie FAST peut être utilisée pour réduire la propagation de la tuberculose ou de la tuberculose mul- tirésistante dans les environnements suivants : les hôpitaux, les cliniques, les prisons et d’autres types d’établissement tels que les centres d’accueil pour sans abri ou les ca...mps de réfugiés.
more
Assurer des prestations optimales dans la chaîne de soins destinés aux patients tuberculeux
Deuxième édition - Juin 2018
